Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$40.29 USD
+0.65 (1.64%)
Updated Sep 12, 2024 04:00 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
GPCR 40.29 +0.65(1.64%)
Will GPCR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GPCR
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
Other News for GPCR
16 new GLP-1 weight-loss drugs could be launched by 2029: report
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Structure Therapeutics Appoints Angus C. Russell to Board of Directors
Altimmune: Emerging Position In Competitive Space, But Risks Remain
Statement from President Biden on anti-obesity medications pricing